Loading candles…
Sakar Healthcare Ltd, incorporated in 2004 and headquartered in Ahmedabad, Gujarat, operates in the pharmaceuticals and healthcare industries. The company functions as an integrated pharmaceutical entity that covers research and development, manufacturing, marketing, and contract development and manufacturing organization (CDMO) services. It offers a range of products including small-volume parenterals (SVP), oral solids such as tablets and capsules, and liquid orals across various therapeutic segments. Serving both domestic and international markets, Sakar Healthcare works as an independent manufacturer and a CDMO, operating across the healthcare value chain.
This page is a live market overview for SAKAR HEALTHCARE LIMITED (SAKAR) on the NSE. As a listed security, SAKAR HEALTHCARE LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for SAKAR before placing trades on tick2trade.
As of the latest feed, SAKAR last traded at ₹924.65 on NSE, up ₹4.95 (0.54%) from the previous close of ₹919.7. Today's session range is ₹908.3 – ₹941, against a 52-week band of ₹311 – ₹960. Traded volume today stands at 82.64K shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for SAKAR in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether SAKAR is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for SAKAR HEALTHCARE LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in SAKAR. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated SAKAR option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 24 Jul 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and other business matters | 12 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and other business matters | 5 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and other business matters | 7 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters | 25 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 15 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.